About Savient Pharmaceutical:

Savient Pharmaceuticals, Inc. is a specialty pharmaceuticals company engaged in the research, development, manufacture, and marketing of pharmaceutical products that address unmet medical needs in both niche and larger market segments.

Development, manufacture, distribution and sale of its oral liquid products are carried out through Rosemont in the United Kingdom.

Products on the Market

Oxandrin® is an oral anabolic agent indicated as adjunctive therapy to promote weight gain following weight loss due to extensive surgery, chronic infection, or severe trauma.

Bio-TropinTM, Savient’s genetically engineered human growth hormone, is indicated for the treatment of pituitary growth hormone deficiency in children.

BioLon® is a 1% solution of sodium hyaluronate used as a surgical aid to protect corneal endothelium during cataract extraction procedures, intraocular lens implantation, and anterior segment surgery

Delatestryl® is Savient’s injectable testosterone replacement therapy for the treatment of conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

Bio-Hep-B®, the first recombinant hepatitis B vaccine

Silkis® is a vitamin D derivative for the topical treatment of psoriasis

Sodium hyaluronate for osteoarthritis

The Clinical Pipeline:



Prosaptide is a peptide sequence in development for the treatment of peripheral neuropathic pain, a serious and debilitating condition that usually affects the feet and legs. A Phase II human clinical trial of Prosaptide demonstrated that it effectively decreases pain associated with diabetic peripheral neuropathy without deleterious side effects. A Phase II study in HIV/AIDS neuropathic pain is in progress to supplement these findings.

Puricase® is Savient’s genetically engineered polyethylene glycol (PEG) conjugate of uricase, an enzyme that converts uric acid into a highly soluble and more easily excreted product. A Phase II study of Puricase for the elimination of excess uric acid in individuals with symptomatic gout that is unresponsive to conventional treatment is in progress. Puricase has received FDA Orphan Drug designation for this indication.

FibrimageTM is a diagnostic agent for the detection of deep vein thrombosis (DVT),

Home Page

Key Statistics for Savient

Basic Chart for Savient

Analyst Opinion

Analysts Estimates

NEWS